comparemela.com

Latest Breaking News On - Autosomal dominant polycystic kidney disease - Page 8 : comparemela.com

Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates

/PRNewswire/ Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines.

United-states
San-diego
California
Cris-calsada
Sarah-sutton
Jay-hagan
Regulus-therapeutics-inc
Program-updates
Rnas-the-company-or-regulus
Nasdaq
Enterprise-associates
Development-rd-expenses

Romsey mum gets lifesaving surgery after husband donates his kidney

A Romsey mum has undergone lifesaving surgery after her husband of 24 years donated his own kidney to her

Chandlers-ford
Hampshire
United-kingdom
Romsey
Beccy-hoddinott-isaac
Mum-of-two-beccy-hoddinott-isaac
Queen-alexandra-hospital
Autosomal-dominant-polycystic-kidney-disease
Wessex-renal

Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates

/PRNewswire/ Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines.

United-states
San-diego
California
Morgan-carlson
Edmund-lee
Claire-padgett
Rekha-garg
Jay-hagan
Regulus-therapeutics-inc
Chronic-kidney-disease-drug-development-summit
Program-updates
Nasdaq

Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates

Enrollment progressing in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Top-line data in the first cohort of RGLS8429-treated ADPKD patients anticipated in second half of .

United-states
San-diego
California
Morgan-carlson
Edmund-lee
Claire-padgett
Rekha-garg
Jay-hagan
Development-rd-expenses
Prnewswire-regulus-therapeutics-inc
Exchange-commission
Clinical-development

Polycystic Kidney Disease Drugs Market Expand CAGR of ~7%, Driving Factors, Size, Revenue & Opportunities 2023-2033

The global polycystic kidney disease drugs market is expected to reach an estimated value of ~USD 732 Million by 2033, by expanding at a CAGR of ~7%.

Qatar
Australia
United-states
Brazil
China
Austria
Russia
Woman
Bahrain
Mexico
New-zealand
India

vimarsana © 2020. All Rights Reserved.